Sidley has advised Rigel Pharmaceuticals. Ropes & Gray has advised Pfizer. Rigel Pharmaceuticals, Inc. has entered into an exclusive global license agreement with Arvinas, Inc. and...
Rigel Pharmaceuticals Secures Global License for VEPPANU from Arvinas and Pfizer in $320 Million Deal
Shionogi Increases Stake in ViiV Healthcare Through $2.125 Billion Transaction with GSK and Pfizer
Wachtell, Lipton, Rosen & Katz has advised Pfizer. Skadden has advised Shionogi. Slaughter and May has advised GSK plc. GSK plc and Shionogi & Co., Ltd...
Pfizer to Acquire Metsera in $4.9 Billion Biopharmaceutical Deal
Wachtell, Lipton, Rosen & Katz has advised Pfizer. Paul, Weiss, Rifkind, Wharton & Garrison has advised Metsera. Pfizer Inc. has entered into an agreement to acquire...
GlaxoSmithKline Prevails in Delaware Supreme Court Over Zantac Litigation Expert Testimony
Eckert Seamans Cherin & Mellott LLC with Kirkland & Ellis LLP and Dechert LLP have advised GlaxoSmithKline LLC. McCarter & English with Williams & Connolly LLP...
Pfizer’s £2.5 Billion Offering and Share Buyback of Haleon Shares
Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Pfizer. Pfizer Inc. (NYSE: PFE) announced the sale of approximately 618 million ordinary shares in...
Pfizer’s £2.5 Billion Sale of Ordinary Shares in Haleon
Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Pfizer. Pfizer Inc. (NYSE: PFE) announced the sale of 700 million ordinary shares in Haleon...
Pfizer’s $3.57 Billion Sale of Shares in Haleon
Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Pfizer. On October 1, 2024, Pfizer Inc. (NYSE: PFE) announced the sale of 640 million...
Haleon’s $3.5 Billion Global Offer by Pfizer and Share Buyback
Wachtell, Lipton, Rosen & Katz served as legal advisor to Pfizer on the transaction. Haleon plc (LSE/NYSE: HLN) announced that Pfizer Inc. (NYSE: PFE) intends to...
Basilea Pharmaceutica’s Asset Purchase Agreement With Amplyx Pharmaceuticals
Lenz & Staehelin is advising Pfizer and Amplyx Pharmaceuticals on this transaction. Basilea Pharmaceutica, a commercial-stage biopharmaceutical company, entered into an asset purchase agreement with Amplyx Pharmaceuticals,...
Alexion, AstraZeneca Rare Disease in Deal with Pfizer
Covington & Burling advised Alexion on the transaction while Arnold & Porter represented Pfizer. AstraZeneca Rare Disease announced its entry into a definitive purchase and license agreement...
Pfizer’s Strategic Collaboration with Flagship Pioneering
Ropes & Gray advised Pfizer on the deal. Pfizer announced a strategic collaboration with Flagship Pioneering to create a new pipeline of innovative medicines. The collaboration...
Pfizer’s $25 Million Strategic Investment in CellCentric
Ropes & Gray advised Pfizer on the deal. Pfizer announced its strategic investment in and collaboration with CellCentric, which includes $25 million to help finance further development...